StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.04 (-10.90%)

Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%

Rein Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Rein Therapeutics's total assets was $65.97M at Jun 30, 2026. For fiscal 2025 it was $24.16M, down 61.2% from the year before. The highest annual figure on record is $106.01M in fiscal 2023.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$24.16M-61.2%
FY2024Dec 31, 2024$62.19M-41.3%
FY2023Dec 31, 2023$106.01M+381.7%
FY2022Dec 31, 2022$22.01M-54.6%
FY2021Dec 31, 2021$48.48M+196.7%
FY2020Dec 31, 2020$16.34M-38.3%
FY2019Dec 31, 2019$26.47M-12.7%
FY2018Dec 31, 2018$30.31M-42.5%
FY2017Dec 31, 2017$52.69M+139.3%
FY2016Dec 31, 2016$22.02M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$65.97M+14.8%
Q1 FY2026Mar 31, 2026$26.29M-54.4%
Q4 FY2025Dec 31, 2025$24.16M-61.2%
Q3 FY2025Sep 30, 2025$53.71M-48.5%
Q2 FY2025Jun 30, 2025$57.48M-47.5%
Q1 FY2025Mar 31, 2025$57.63M-41.9%
Q4 FY2024Dec 31, 2024$62.19M-41.3%
Q3 FY2024Sep 30, 2024$104.22M+712.8%
Q2 FY2024Jun 30, 2024$109.40M+681.9%
Q1 FY2024Mar 31, 2024$99.19M+478.1%
Q4 FY2023Dec 31, 2023$106.01M+381.7%
Q3 FY2023Sep 30, 2023$12.82M-52.9%
Q2 FY2023Jun 30, 2023$13.99M-58.6%
Q1 FY2023Mar 31, 2023$17.16M-57.4%
Q4 FY2022Dec 31, 2022$22.01M-54.6%
Q3 FY2022Sep 30, 2022$27.23M-50.3%
Q2 FY2022Jun 30, 2022$33.77M-44.2%
Q1 FY2022Mar 31, 2022$40.26M-37.8%
Q4 FY2021Dec 31, 2021$48.48M+196.7%
Q3 FY2021Sep 30, 2021$54.77M+146.3%
Q2 FY2021Jun 30, 2021$60.53M+131.7%
Q1 FY2021Mar 31, 2021$64.67M+217.4%
Q4 FY2020Dec 31, 2020$16.34M-38.3%
Q3 FY2020Sep 30, 2020$22.24M-34.5%
Q2 FY2020Jun 30, 2020$26.13M-35.0%
Q1 FY2020Mar 31, 2020$20.37M-9.0%
Q4 FY2019Dec 31, 2019$26.47M-12.7%
Q3 FY2019Sep 30, 2019$33.95M-11.0%
Q2 FY2019Jun 30, 2019$40.19M-5.6%
Q1 FY2019Mar 31, 2019$22.40M-51.1%
Q4 FY2018Dec 31, 2018$30.31M-42.5%
Q3 FY2018Sep 30, 2018$38.13M-35.4%
Q2 FY2018Jun 30, 2018$42.58M+181.9%
Q1 FY2018Mar 31, 2018$45.83M+108.1%
Q4 FY2017Dec 31, 2017$52.69M–
Q3 FY2017Sep 30, 2017$59.04M–
Q2 FY2017Jun 30, 2017$15.11M–
Q4 FY2016Dec 31, 2016$22.02M–

More Rein Therapeutics figures

See a number that looks wrong?